# A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

> **NCT07505615** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ding-Wei Ye** · enrollment: 20 (actual)

## Conditions studied

- NMIBC

## Interventions

- **DRUG:** VG161 via Intravesical Instillation

## Key facts

- **NCT ID:** NCT07505615
- **Lead sponsor:** Ding-Wei Ye
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-12
- **Primary completion:** 2023-04-28
- **Final completion:** 2023-05-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07505615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07505615, "A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07505615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*